日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer

肿瘤突变可预测原发性HER2阳性乳腺癌对HER2靶向治疗的耐药性

Van Mackelenbergh, Marion T; Pfarr, Nicole; Weber, Karsten; Untch, Michael; Solbach, Christine; Schneeweiss, Andreas; Jank, Paul; Blohmer, Jens; Treue, Denise; Schmatloch, Sabine; Lehmann, Annika; Hanusch, Claus; Link, Theresa; Sers, Christine; Bjelic-Radisic, Vesna; Hummel, Michael; Huober, Jens; Schmitt, Wolfgang D; Fasching, Peter A; Aktas, Bahriye; Rhiem, Kerstin; Reinisch, Mattea; Nekljudova, Valentina; Denkert, Carsten; Loibl, Sibylle

Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer

基于生理的瑞博西尼药代动力学:药物相互作用及早期乳腺癌器官损害药代动力学

Ji, Yan; Huth, Felix; Wang, Craig; Schiller, Hilmar; Combes, Francois Pierre; Crown, John; Fasching, Peter A; Zarate, Juan Pablo; Untch, Michael

ABC8 Consensus: Assessment by a German Group of Experts

ABC8共识:德国专家组的评估

Ditsch, Nina; Untch, Michael; Fasching, Peter A; Briest, Susanne; Ettl, Johannes; Haidinger, Renate; Lüftner, Diana; Maurer, Christian; Müller, Volkmar; Park-Simon, Tjoung-Won; Ruckhäberle, Eugen; Schem, Christian; Schumacher-Wulf, Eva; Harbeck, Nadia; Wuerstlein, Rachel

Correction: Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations

更正:早期乳腺癌患者的治疗:第19届圣加仑国际乳腺癌共识会议以德国治疗建议为背景进行讨论

Untch, Michael; Banys-Paluchowski, Maggie; Brucker, Sara Y; Denkert, Carsten; Fasching, Peter A; Haidinger, Renate; Harbeck, Nadia; Janni, Wolfgang; Krug, David; Loibl, Sibylle; Lüftner, Diana; Michel, Laura; Schumacher-Wulf, Eva; Solbach, Christine; Würstlein, Rachel; Huober, Jens; Ditsch, Nina

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

瑞博西尼联合内分泌治疗激素受体阳性/ERBB2阴性早期乳腺癌:NATALEE随机临床试验的4年结果

Fasching, Peter A; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Xu, Binghe; Loi, Sherene; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Hortobagyi, Gabriel N; Slamon, Dennis J; Fresco, Rodrigo; Zarate, Juan Pablo; Li, Zheng; Waters, Sorcha; Hurvitz, Sara A

Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study

符合辅助阿贝西利或瑞博西尼治疗条件的乳腺癌患者的患病率和预后:一项全国性人群研究

Liu, Xingrong; Binicy, Behnaz; Acs, Balazs; Eriksson Bergman, Louise; Loibl, Sibylle; Gnant, Michael; Untch, Michael; Valachis, Antonios; Bergh, Jonas; Hartman, Johan; Foukakis, Theodoros; Matikas, Alexios

RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs.

RBM10 缺失通过细胞骨架和细胞外基质 mRNA 的异常剪接促进转移

Krishnamoorthy Gnana P, Glover Anthony R, Untch Brian R, Sigcha-Coello Nickole, Xu Bin, Vukel Dina, Liu Yi, Tiedje Vera, Pineda Jose Mario Bello, Berman Katherine, Tamarapu Prasanna P, Acuña-Ruiz Adrian, Saqcena Mahesh, de Stanchina Elisa, Boucai Laura, Ghossein Ronald A, Knauf Jeffrey A, Abdel-Wahab Omar, Bradley Robert K, Fagin James A

Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial

接受瑞博西尼联合非甾体类芳香化酶抑制剂治疗的 HR+/HER2- 早期乳腺癌患者的健康相关生活质量:NATALEE 试验结果

Fasching, Peter A; Slamon, Dennis; Nowecki, Zbigniew; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Chan, Arlene; Chia, Stephen; Martín, Miguel; Rugo, Hope S; Loi, Sherene; Hurvitz, Sara; Untch, Michael; Afenjar, Karen; Fresco, Rodrigo; Danyliv, Andriy; Ferrusi, Ilia; Li, Zheng; Hortobagyi, Gabriel

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

辅助性利博西尼联合非甾体类芳香化酶抑制剂治疗HR阳性/HER2阴性早期乳腺癌患者:NATALEE研究疗效结果的5年随访及更新的总生存期

Crown, J; Stroyakovskii, D; Yardley, D A; Huang, C-S; Fasching, P A; Bardia, A; Chia, S; Im, S-A; Martin, M; Xu, B; Barrios, C H; Untch, M; Moroose, R; Hurvitz, S A; Hortobagyi, G N; Slamon, D J; Visco, F; Spera, G; Zarate, J P; Halligan, D; Li, Z; Loi, S

Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)

新辅助地诺单抗治疗对高危早期乳腺癌的长期疗效(GeparX)

Link, T; Reinisch, M; Just, M; Untch, M; Filmann, N; Stötzer, O; Denkert, C; Bjelic-Radisic, V; Wimberger, P; Thill, M; Rhiem, K; Huober, J; Solbach, C; Hanusch, C; Engels, K; Fasching, P A; Schneeweiss, A; Nekljudova, V; Holtschmidt, J; Blohmer, J-U; Loibl, S